Two Novel CYP2D6*10 Haplotypes As Possible Causes of a Poor Metabolic Phenotype in Japanese

被引:26
作者
Matsunaga, Masayuki [1 ,2 ]
Yamazaki, Hiroshi [2 ]
Kiyotani, Kazuma [2 ]
Iwano, Shunsuke [2 ]
Saruwatari, Jyunji [3 ]
Nakagawa, Kazuko [3 ]
Soyama, Akiko [4 ]
Ozawa, Shogo [4 ]
Sawada, Jun-ichi [4 ]
Kashiyama, Eiji [1 ]
Kinoshita, Moritoshi [1 ]
Kamataki, Tetsuya [2 ]
机构
[1] Otsuka Pharmaceut Co Ltd, Kawaguchi, Tokushima 7710192, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido, Japan
[3] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto, Japan
[4] Natl Inst Hlth Sci, Tokyo, Japan
关键词
CATALYTIC-ACTIVITY; CYTOCHROME-P450; 2D6; CYP2D6;
D O I
10.1124/dmd.108.026096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the course of sequencing for the CYP2D6 gene, we found a novel single nucleotide polymorphism of g.3318G>A (E383K) associated with CYP2D6*10, termed as CYP2D6*72. We also found a g.1611T>A (F120I) in the CYP2D6*49, which was previously identified as a CYP2D6*10-associated allele in an independent Japanese population. To clarify the effects of these novel CYP2D6*10 haplotypes on the functions of CYP2D6, kinetic analysis for dextromethorphan O-demethylation was performed using the Escherichia coli expression system and human liver microsomes. The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1. Liver microsomes from a human subject genotyped as CYP2D6*10/*49 also showed a reduced dextromethorphan O-demethylase activity. CYP2D6.49 formed a 7-hydroxydextromethorphan, with a roughly similar V(max)/K(m) value to that of O-demethylation. These results suggest that these two CYP2D6*10 haplotypes are possible causes of interindividual variation in the activities and the substrate specificity of CYP2D6.
引用
收藏
页码:699 / 701
页数:3
相关论文
共 10 条
[1]   Phe120 contributes to the regiospecificity of cytochrome P450 2D6:: mutation leads to the formation of a novel dextromethorphan metabolite [J].
Flanagan, JU ;
Maréchal, JD ;
Ward, R ;
Kemp, CA ;
Mclaughlin, LA ;
Sutcliffe, MJ ;
Roberts, GCK ;
Paine, MJI ;
Wolf, CR .
BIOCHEMICAL JOURNAL, 2004, 380 :353-360
[2]   Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].
Ingelman-Sundberg, M .
PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13
[3]   High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli [J].
Iwata, H ;
Fujita, K ;
Kushida, H ;
Suzuki, A ;
Konno, Y ;
Nakamura, K ;
Fujino, A ;
Kamataki, T .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) :1315-1325
[4]   PCR-based genotyping for duplicated and deleted CYP2D6 genes [J].
Johansson, I ;
Lundqvist, E ;
Dahl, ML ;
IngelmanSundberg, M .
PHARMACOGENETICS, 1996, 6 (04) :351-355
[5]   CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability [J].
Nakamura, K ;
Ariyoshi, N ;
Yokoi, T ;
Ohgiya, S ;
Chida, M ;
Nagashima, K ;
Inoue, K ;
Kodama, T ;
Shimada, N ;
Kamataki, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (03) :969-973
[6]   Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates [J].
Ramamoorthy, Y ;
Tyndale, RF ;
Sellers, EM .
PHARMACOGENETICS, 2001, 11 (06) :477-487
[7]  
Soyama Akiko, 2004, Drug Metab Pharmacokinet, V19, P313, DOI 10.2133/dmpk.19.313
[8]   Analysis of the CΥP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population [J].
Tateishi, T ;
Chida, M ;
Ariyoshi, N ;
Mizorogi, Y ;
Kamataki, T ;
Kobayashi, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :570-575
[9]  
Yamaori Satoshi, 2004, Drug Metab Pharmacokinet, V19, P120, DOI 10.2133/dmpk.19.120
[10]  
Yamazaki Hiroshi, 2003, Drug Metab Pharmacokinet, V18, P269, DOI 10.2133/dmpk.18.269